OTCPK:BMCS

Stock Analysis Report

Executive Summary

BioTech Medics, Inc. operates as a medical-based holding company.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • BioTech Medics has significant price volatility in the past 3 months.
  • BioTech Medics's last earnings update was 2755 days ago.
  • BioTech Medics is not covered by any analysts.

Share Price & News

How has BioTech Medics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BMCS

0.8%

US Healthcare

1.3%

US Market


1 Year Return

218.2%

OTCPK:BMCS

-8.2%

US Healthcare

2.0%

US Market

BMCS outperformed the Healthcare industry which returned -8.2% over the past year.

BMCS outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

BMCSIndustryMarket
7 Day0%0.8%1.3%
30 Day184.6%-1.5%3.9%
90 Day169.2%-0.5%3.4%
1 Year218.2%218.2%-6.8%-8.2%4.2%2.0%
3 Year133.3%133.3%30.2%24.9%47.2%37.6%
5 Year250.0%250.0%63.6%53.9%60.5%42.9%

Price Volatility Vs. Market

How volatile is BioTech Medics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioTech Medics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether BioTech Medics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioTech Medics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine BioTech Medics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioTech Medics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioTech Medics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioTech Medics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioTech Medics performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, BioTech Medics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is BioTech Medics's financial position?


In this section we usually analyse BioTech Medics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. BioTech Medics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of BMCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when BioTech Medics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is BioTech Medics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioTech Medics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioTech Medics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioTech Medics has not reported any payouts.

Unable to verify if BioTech Medics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioTech Medics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioTech Medics's salary, the management and board of directors tenure and is there insider trading?


CEO

Keith Houser (70yo)

14.8yrs

Tenure

0

Mr. Keith A. Houser has been the Chairman and Chief Executive Officer of BioTech Medics, Inc. since December 7, 2004 and serves as its Interim President. Mr. Houser has over 32 years of both private and pu ...


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Keith Houser (70yo)

    Chairman

    • Tenure: 14.8yrs
  • James Nairne

    Chief Financial Officer

    • Tenure: 0yrs
  • Tom Wood

    Senior Vice President of Sales

    • Tenure: 0yrs

Board Members

  • Keith Houser (70yo)

    Chairman

    • Tenure: 14.8yrs
  • Robert Honigsfeld

    Member of Advisory Board

    • Tenure: 0yrs
  • Brenda Sewell

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

BioTech Medics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioTech Medics, Inc.
  • Ticker: BMCS
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$1.206m
  • Shares outstanding: 172.36m
  • Website: https://null

Location

  • BioTech Medics, Inc.
  • PO Box 93476
  • Southlake
  • Texas
  • 76092-0114
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMCSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 2004

Biography

BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:02
End of Day Share Price2019/09/13 00:00
Earnings2011/12/31
Annual Earnings2011/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.